© 2023 BioMarin. All rights reserved.

Investors & Media

BioMarin R&D Day

September 12, 2023

Webcast Replay Presentation

Stock Quote
Transforming Lives Through Genetic Discovery

We seek to make a big difference in genetic disorders. At BioMarin, through our unparalleled expertise in genetics and molecular biology, we will continue to develop targeted therapies that address the root cause of the conditions we seek to treat. Applying our knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most.

Fast Facts

>$2 Billion

in 2022 FY Total Revenues

78 Countries

Commercial Footprint

World-class Capabilities

Manufacturing, R&D, Regulatory, and Commercial

"Core 4" Product Framework

Genetic, Targeted, Assessable, Transformational

Wednesday, November 1, 2023
1:30pm PDT
Tuesday, September 12, 2023
1:25pm EDT

All Events

Latest News
Nov 28, 2023

ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in Germany SAN RAFAEL, Calif., Nov. 28, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global...

Nov 1, 2023

• Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO® and ROCTAVIAN® Net Product Revenue Guidance Adjusted for Full-year 2023 • VOXZOGO Now Approved...

Nov 1, 2023

Mr. Hardy Brings More than 30 Years of Industry Experience, Most Recently as CEO of Genentech Mr. Bienaimé Served as CEO for 18 Years and as Chairman since 2015, Steering BioMarin to...

All Press Releases

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.


Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.


Learn More


Our executive team is made up of tech leaders with diverse backgrounds and a singular focus.



Contact Us

Investor Relations

Media & Press

Email Alerts

Sign up for alerts to receive updates on company announcements, financial information and more!